Advances in implantable cardioverter defibrillator therapy

John Rickard, Bruce L. Wilkoff

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Since the first implant in 1980, implantable cardioverter defibrillator (ICD) technology has progressed rapidly. Modern ICDs have hundreds of programmable options with the general goal of preventing inappropriate shocks and providing shocks for truly life threatening symptomatic ventricular arrhythmias. New studies on ICD programming have shown the benefits of prolonged detection intervals in reaching this goal. Anti-tachycardia pacing (ATP) therapy has become an important adjunct to defibrillator shocks. Remote monitoring technologies have surfaced which have been shown to identify arrhythmias and problems with the device in an expedient fashion. The subcutaneous ICD offers the advantage of avoiding intravascular leads and their inherent risks. Lastly, the current understanding of the effects of MRI in ICD patients has advanced creating new opportunities to provide MRI safely to such patients.

Original languageEnglish (US)
Pages (from-to)291-299
Number of pages9
JournalExpert review of cardiovascular therapy
Issue number3
StatePublished - Mar 3 2016


  • ATP
  • ICD
  • ICD programming
  • MRI and ICD
  • subcutaneous ICD

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Advances in implantable cardioverter defibrillator therapy'. Together they form a unique fingerprint.

Cite this